Cagri is a long-acting analogue of amylin, a peptide hormone released alongside insulin from pancreatic beta cells. It activates amylin receptors and the related calcitonin receptor. Research has measured satiety signalling, food intake and gastric emptying. A fatty acid chain lets it bind albumin, which extends its half-life to about a week.
The numbers that define Cagri and how it is being studied. For laboratory research use only.
~7 days
Plasma Half-Life
Albumin-bound lipidated design
2
Receptor Families
Amylin (AMY1-3) and calcitonin (CTR)
4
Research Areas
Amylin Receptor Signalling
Satiety Pathways
Combination Research
How It Works
How Cagri works
The pathways Cagri acts on - and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
Amylin Receptor Agonism
AMY
Binds amylin receptors (calcitonin receptor paired with RAMP1-3). Published characterisation describes satiety signalling, slowed gastric emptying and suppression of post-meal glucagon in study models.
Satiety signalling measured
Gastric emptying measured
Post-meal glucagon measured
Calcitonin Receptor Co-Activation
CTR
Also activates the calcitonin receptor directly, a non-selective profile examined alongside its amylin receptor activity. Hindbrain regions such as the area postrema are the main sites studied.
Calcitonin receptor agonism
Hindbrain (area postrema) signalling
Food intake measured
Extended Half-Life Design
PK
Structural changes reduce the fibrillation seen with native amylin, and a fatty-acid chain confers reversible albumin binding, extending the plasma half-life to roughly one week in research models.
~7-day half-life
Albumin-binding modification
Reduced fibrillation vs native amylin
Uses & Applications
What Cagri is researched for
The main areas Cagri is being studied for - and the study-reported figures behind them.
Metabolic
Amylin Receptor Research
Amylin signalling is a growing focus of metabolic research, and Cagri is a long-acting amylin analogue used as a reference compound in that work.
Combination
Amylin + GLP-1 Research
Because amylin and GLP-1 act through different receptors, Cagri is studied alongside GLP-1 receptor agonists such as GLP-1 S in combination research.
Endocrine
Glycemic Pathway Research
Amylin's effects on post-meal glucagon and gastric emptying make Cagri a subject of glycemic pathway research.
Neuroscience
Hindbrain Satiety Circuitry
Amylin receptors in the area postrema and connected hindbrain circuits modulate satiety, a focus of ongoing neuroscience research.
Study-reported magnitudes
Representative figures from published research. Bars fill as you scroll.
HPLC Purity (lot COA)≥99%
Sterility & Endotoxin ScreenPASSED
Net Content & IdentityPASSED
Figures are representative of published research findings and shown for reference.
Molecular Structure
The Cagri molecule
An interactive 3D model rendered from the compound record - rotate and explore its structure.
C194H312N54O59S2
Molecular formula
C194H312N54O59S2
Molecular weight
4409 g/mol
Sequence length
peptide
Physical form
Lyophilized powder
Documented purity
≥99% by HPLC
How Long It Lasts
Duration & clearance
How Cagri clears from circulation, modeled from its documented ~~7 days half-life. The curve draws as you scroll.
Cagri · ~~7 days
Reference · rapid clearance
Compound Information
Full specification
Compound Class
Long-acting amylin analogue
Research Name
Cagri
Target
Amylin receptors (AMY1-3) and calcitonin receptor (CTR)
Form
Lyophilized powder
Molecular Weight
4,409 g/mol
Purity
≥99% (HPLC verified)
Testing
Third-party HPLC, Mass Spec, Endotoxin
Half-Life
~7 days
Storage
-20°C for long-term stability
Solubility
Water-soluble
COA
Included with every order
FAQ
Common questions about Cagri
Cagri is a long-acting analogue of the pancreatic hormone amylin. It activates amylin receptors and the calcitonin receptor; published characterisation describes satiety signalling, slowed gastric emptying and suppression of post-meal glucagon.
The GLP compounds act on incretin receptors (GLP-1, GIP, glucagon). Cagri acts on a different system entirely: amylin and calcitonin receptors. That is why it is studied alongside GLP-1 receptor agonists in combination research.
Cagri has a molecular weight of 4,409 g/mol. Every vial is supplied at ≥99% purity, verified by HPLC, with a Certificate of Analysis included.
Store lyophilized vials at -20°C for long-term stability, protected from light and moisture.
No. Cagri is sold strictly as a research compound for laboratory and in-vitro use only. It is not intended for human or animal consumption, diagnosis, or treatment.
Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
